Part 2 Preface: Immune Checkpoint Inhibitors and Adverse Autoimmune Manifestations

Crit Rev Immunol. 2022;42(4):v-vi. doi: 10.1615/CritRevImmunol.v42.i4.10.

Authors

Vipin Kumar¹, Benjamin Bonavida²

Affiliations

¹ Laboratory of Immune Regulation, Department of Medicine, UCSD School of Medicine, La Jolla, CA 92093, USA.
² Department of Microbiology, Immunology, & Molecular Genetics, David Geffen School of Medicine at UCLA, Johnson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90025-1747, USA.

PMID: 37022355
DOI: 10.1615/CritRevImmunol.v42.i4.10

No abstract available

MeSH terms

Antineoplastic Agents, Immunological* / therapeutic use
Autoimmune Diseases*
Humans
Immune Checkpoint Inhibitors / adverse effects
Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors
Antineoplastic Agents, Immunological